Geovax Labs Company Profile (OTCMKTS:GOVX)

About Geovax Labs (OTCMKTS:GOVX)

Geovax Labs logoGeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:GOVX
  • CUSIP: N/A
  • Web: www.geovax.com
Capitalization:
  • Market Cap: $2.26 million
  • Outstanding Shares: 58,719,000
Average Prices:
  • 50 Day Moving Avg: $0.05
  • 200 Day Moving Avg: $0.06
  • 52 Week Range: $0.04 - $0.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 0.04
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $1.08 million
  • Price / Sales: 2.09
  • Book Value: ($0.02) per share
  • Price / Book: -1.75
Profitability:
  • EBIDTA: ($2,500,000.00)
  • Net Margins: -371.99%
  • Return on Assets: -388.20%
Debt:
  • Current Ratio: 2.40%
  • Quick Ratio: 2.40%
Misc:
  • Average Volume: 249,708 shs.
  • Beta: 0.17
 

Frequently Asked Questions for Geovax Labs (OTCMKTS:GOVX)

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) released its earnings results on Wednesday, November, 19th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. View Geovax Labs' Earnings History.

Who are some of Geovax Labs' key competitors?

How do I buy Geovax Labs stock?

Shares of Geovax Labs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Geovax Labs stock cost?

One share of Geovax Labs stock can currently be purchased for approximately $0.04.

Analyst Ratings

Consensus Ratings for Geovax Labs (OTCMKTS:GOVX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Geovax Labs (OTCMKTS:GOVX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Geovax Labs (OTCMKTS:GOVX)
Earnings by Quarter for Geovax Labs (OTCMKTS:GOVX)
Earnings History by Quarter for Geovax Labs (OTCMKTS:GOVX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/19/2014($0.03)($0.02)ViewN/AView Earnings Details
8/22/2014($0.03)($0.03)ViewN/AView Earnings Details
5/2/2014($0.03)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Geovax Labs (OTCMKTS:GOVX)
Current Year EPS Consensus Estimate: $-0.1200 EPS
Next Year EPS Consensus Estimate: $1.0600 EPS

Dividends

Dividend History for Geovax Labs (OTCMKTS:GOVX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Geovax Labs (OTCMKTS:GOVX)
Insider Ownership Percentage: 7.60%
Insider Trades by Quarter for Geovax Labs (OTCMKTS:GOVX)
Insider Trades by Quarter for Geovax Labs (OTCMKTS:GOVX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2015Randal D ChaseDirectorBuy10,000$0.19$1,900.00View SEC Filing  
4/23/2015Mark ReynoldsCFOBuy30,000$0.17$5,100.00View SEC Filing  
4/20/2015Randal D ChaseDirectorBuy30,000$0.17$5,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Geovax Labs (OTCMKTS:GOVX)
Latest Headlines for Geovax Labs (OTCMKTS:GOVX)
Source:
DateHeadline
bizjournals.com logoAtlanta biotech firm GeoVax raises $1 million in stock sale
www.bizjournals.com - May 9 at 12:39 PM
finance.yahoo.com logoGeoVax Reports 2017 First Quarter Financial Results and Development Program Updates
finance.yahoo.com - May 8 at 5:15 PM
finance.yahoo.com logoGeoVax to Present Zika Vaccine Data at the 20th Annual Conference on Vaccine Research
finance.yahoo.com - April 10 at 11:19 AM
finance.yahoo.com logoGeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program
finance.yahoo.com - April 3 at 11:59 AM
finance.yahoo.com logoGeoVax Reports on Vaccine Development Progress
finance.yahoo.com - March 27 at 11:25 AM
finance.yahoo.com logoGeoVax Reports Promising Results for Zika Vaccine
finance.yahoo.com - March 20 at 7:14 PM
finance.yahoo.com logoGeoVax Announces Collaboration with American Gene Technologies for HIV Functional Cure
finance.yahoo.com - March 14 at 12:20 PM
finance.yahoo.com logoGOVX: Multiple Progress Made in the Last Two Months
finance.yahoo.com - February 14 at 6:41 PM
finance.yahoo.com logoGeoVax Media and Presentation Update
finance.yahoo.com - February 2 at 6:07 PM
reuters.com logoBRIEF-GeoVax announces initiation of HIV Human Clinical Trial
www.reuters.com - January 23 at 11:20 AM
finance.yahoo.com logoGeoVax Announces Initiation of HIV Human Clinical Trial
finance.yahoo.com - January 23 at 11:20 AM
finance.yahoo.com logoGeoVax to Collaborate with Georgia State University on Development of Therapeutic Hepatitis B Vaccine
finance.yahoo.com - January 17 at 9:20 AM
finance.yahoo.com logoGeoVax and Burnet Institute to Join Forces to Develop Malaria Vaccine
finance.yahoo.com - January 9 at 4:20 PM
bizjournals.com logoZika vaccine developer names new chief scientific officer
www.bizjournals.com - January 3 at 11:57 AM
finance.yahoo.com logoGeoVax Announces Appointment of Farshad Guirakhoo, PhD as Chief Scientific Officer
finance.yahoo.com - December 14 at 6:11 PM
finance.yahoo.com logoGeoVax to Conduct Investor and Partnering Meetings During 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 7 at 10:40 AM
finance.yahoo.com logoGeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses
finance.yahoo.com - December 5 at 11:20 AM
finance.yahoo.com logoGeoVax Observes World AIDS Day
finance.yahoo.com - December 1 at 10:37 AM
finance.yahoo.com logoGOVX: Update on Third Quarter Financials
finance.yahoo.com - November 21 at 10:23 AM
finance.yahoo.com logoGeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program
finance.yahoo.com - November 7 at 5:31 PM
finance.yahoo.com logoGeoVax HIV Vaccine Clinical Data Presented At HIVR4P Conference
finance.yahoo.com - October 20 at 5:19 PM
finance.yahoo.com logoGeoVax to Present at Upcoming Scientific Conferences on Its Hemorrhagic Fever and Zika Vaccine Programs
finance.yahoo.com - October 3 at 9:54 AM
finance.yahoo.com logoGOVX: Progress Made to Advance its Vaccine Programs
finance.yahoo.com - August 29 at 5:11 PM
finance.yahoo.com logoGeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 5 at 5:24 PM
finance.yahoo.com logoUPDATE - GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial
finance.yahoo.com - July 1 at 9:00 AM
finance.yahoo.com logo9:01 am GeoVax announces VNIH filed an INDA w/ the FDA for the conduct of the next human clinical trial of its preventive HIV vaccine
finance.yahoo.com - June 30 at 9:01 AM
finance.yahoo.com logo9:01 am GeoVax announces VNIH filed an INDA w/ the FDA for the conduct of the next human clinical trial of its preventive HIV vaccine
finance.yahoo.com - June 30 at 9:01 AM
finance.yahoo.com logoGeoVax Discusses Zika Vaccine Development at American Society for Virology's 35th Annual Meeting
finance.yahoo.com - June 21 at 2:30 PM
biz.yahoo.com logoGEOVAX LABS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of
biz.yahoo.com - June 16 at 10:10 AM
finance.yahoo.com logoGOVX: GeoVax: Entering into HBV Market
finance.yahoo.com - June 7 at 11:15 AM
finance.yahoo.com logoGOVX: Update on First Quarter Financials
finance.yahoo.com - June 1 at 10:00 AM
finanznachrichten.de logoGeoVax Recognizes National Black HIV/AIDS Awareness Day / Bringing Attention to Minority Health Disparities in HIV/AIDS and the Need for a Vaccine
www.finanznachrichten.de - February 5 at 2:10 PM
nasdaq.com logoIndian Pharma Files For Patent For First Zika Vaccine
www.nasdaq.com - February 3 at 1:38 PM

Social

Chart

Geovax Labs (GOVX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff